Innovación y Calidad en el Sistema Nacional de Salud
Miércoles, 25 de Junio de 2014 17:00h
http://debateSEC.secardiologia.es
Research and Innovation in Cardiovascular Diseases: The EU perspectives
Dr. Karim Berkouk
Deputy Head of Unit. DG Innovation and Research-European Commission
This document provides an overview of Horizon 2020, the EU's framework programme for research and innovation from 2014 to 2020. The key points are:
1) Horizon 2020 has a budget of over €70 billion and aims to boost Europe's global competitiveness through support for research and innovation.
2) It focuses on three main priorities - excellent science, industrial leadership, and tackling societal challenges - to support jobs and growth across the EU.
3) The programme aims to simplify access to funding for all groups including companies, universities, and institutes across Europe and beyond.
Is cardiovascular screening the best option for reducing future cardiovascula...UKFacultyPublicHealth
Universal screening for cardiovascular disease through NHS Health Checks is less effective and equitable than population-wide policy interventions, according to a microsimulation study. The study found that universal screening would prevent around 19,000 cases and 3,000 deaths between 2016-2030, while population-wide policies could prevent 67,000 cases and 8,000 deaths. A combination of population-wide policies and targeted screening in deprived areas could prevent 82,000 cases and 9,000 deaths. The study used an individual-level modeling approach to estimate the potential impact and equity effects of different prevention strategies in England.
The document discusses EU funding opportunities for health research and innovation under Horizon 2020. Horizon 2020 is the EU's 2014-2020 program for research and innovation, with €80 billion allocated. It focuses on three priorities: excellent science, industrial leadership, and societal challenges. In the area of health, challenges include aging populations, disease burden, and pressure on healthcare systems. The goals are to translate science into benefits, improve outcomes, support healthcare sectors, and promote healthy aging. The document provides details on past funding amounts under FP7 and lists several international consortia supported. It outlines the structure and goals of the International Rare Diseases Research Consortium to develop 200 new therapies and means to diagnose rare diseases by 2020.
Procurement: The Cornerstone of Market Access in EuropeMedTech Europe
An overview of how procurement practices impact market access pathways for medical technologies in Europe.
Presentation make by Yves Verboven on 17 February 2015 at the 2nd Annual Medical Device Commercial Leaders Forum.
This document provides an overview of Horizon 2020, the EU's framework programme for research and innovation from 2014 to 2020. The key points are:
1) Horizon 2020 has a budget of over €70 billion and aims to boost Europe's global competitiveness through support for research and innovation.
2) It focuses on three main priorities - excellent science, industrial leadership, and tackling societal challenges - to support jobs and growth across the EU.
3) The programme aims to simplify access to funding for all groups including companies, universities, and institutes across Europe and beyond.
Is cardiovascular screening the best option for reducing future cardiovascula...UKFacultyPublicHealth
Universal screening for cardiovascular disease through NHS Health Checks is less effective and equitable than population-wide policy interventions, according to a microsimulation study. The study found that universal screening would prevent around 19,000 cases and 3,000 deaths between 2016-2030, while population-wide policies could prevent 67,000 cases and 8,000 deaths. A combination of population-wide policies and targeted screening in deprived areas could prevent 82,000 cases and 9,000 deaths. The study used an individual-level modeling approach to estimate the potential impact and equity effects of different prevention strategies in England.
The document discusses EU funding opportunities for health research and innovation under Horizon 2020. Horizon 2020 is the EU's 2014-2020 program for research and innovation, with €80 billion allocated. It focuses on three priorities: excellent science, industrial leadership, and societal challenges. In the area of health, challenges include aging populations, disease burden, and pressure on healthcare systems. The goals are to translate science into benefits, improve outcomes, support healthcare sectors, and promote healthy aging. The document provides details on past funding amounts under FP7 and lists several international consortia supported. It outlines the structure and goals of the International Rare Diseases Research Consortium to develop 200 new therapies and means to diagnose rare diseases by 2020.
Procurement: The Cornerstone of Market Access in EuropeMedTech Europe
An overview of how procurement practices impact market access pathways for medical technologies in Europe.
Presentation make by Yves Verboven on 17 February 2015 at the 2nd Annual Medical Device Commercial Leaders Forum.
The New EU Framework Programme for Research and Innovationmathgear
Horizon 2020 is the new EU framework programme for research and innovation from 2014 to 2020 with a budget of nearly €80 billion. It aims to stimulate economic growth and jobs by supporting research and innovation. The three priorities are excellent science, industrial leadership, and addressing societal challenges. It provides simplified single set of rules and funding rates to make participating easier for organizations. The first calls saw over 36,000 proposals requesting €80 billion in funds, with around 14% success rate.
Presentation at the 3rd European Sustainable Phosphorus Conference (ESPC3), Helsinki, 11 - 13 June 2018, co-organised by the Baltic Sea Action Group (BSAG) and the European Sustainable Phosphorus Platform (ESPP), brought together nearly 300 participants from 30 countries talking about nutrient recycling and stewardship.
See for all information and outcomes www.phosphorusplatform.eu/ESPC3
Euro-Med cooperation in the Horizon
* Regional focus – while acknowledging diversity within the region
* Focus on common challenges – what are the problems that R&I can help addressing, and how?
* Instruments – to support collaborative research, to support R&I policy dialogue, to coordinate initatives by EU, its Member States and MPCs, to integrate programmes/Art 185, to foster innovation !
* Building on ongoing projects –e.g. MEDSPRING, ERANET MED
EuroBioForum 2013 - Day 1 | Wolfgang EberleEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Belgium
Working across disciplines for our health benefit - From successful strategies for biotech and nanotech to Nanotech for Health in Flanders
Wolfgang Eberle
Funded Program Manager Life Science Technologies Imec
=======================================
http://www.eurobioforum.eu
The document provides an overview of Horizon 2020, the European Union's research and innovation programme for 2014-2020. Key points include:
- It has a budget of over €70 billion, a 25% increase from the previous 2007-2013 period.
- It aims to boost jobs and growth by supporting research, innovation and addressing societal challenges.
- It simplifies funding with single rules, faster grants, and less auditing.
- Funding is organized around three priorities: excellent science, industrial leadership, and societal challenges like health, energy, transport and climate.
- It emphasizes challenge-based and cross-disciplinary research with participation from SMEs.
- Horizon 2020 aims to strengthen the
The SME Innovation Instrument, Horizon2020 and Talent Europe. A discussion by...Alberto Minin
I provide a quick introduction to the Meridian Fellowship on Social Innovation and to my project, Talent Europe,
I will then present some of the latest numbers regarding the implementation of the SME Innovation instrument, one of the most innovative parts of the 8th presentation Framework program called Horizon 2020
I will briefly share with you three concepts that I think might be interesting to explore as a basis of a useful comparison between Europe and US science and technology Policy.
What I am seeking to do as a Meridian Fellow is to expand my expertise on science and technology policy and to contribute to the debate around this topic that is developing in Europe. I think that there are better ways to engage and to empower EU talent, and to make it become key player of EU Economic Recovery and competitiveness
The US had been a continuous source of inspiration for the EU debate on science and technology, and more in general on innovation policy.
Later on I will discuss about the SME innovation instrument that had been inspired in part by the SBIR program here in the US.
Not only policy makers and scholars have been guiding this exchange of ideas and experiences, but also US Embassies in Europe have been very important in sharing with Europe some news. I am very familiar with the case of the US Embassies in Italy. The past three Ambassadors have been evangelists of messages and priorities. Ronald Spogli emphasized the role of high tech entrepreneurs in society, David Thorne has focused on the role the digital economy can have a driver of growth, more recently the sitting ambassador, John Phillips is very vocal about the benefits that Italy could derive by a more efficient judiciary system
My experience as scholar, and teacher is telling me that the debate on innovation in Europe is desperately in need of some fresh air and new ideas.
I believe that there are four areas where we can look.
The first one has to do with new original ways to communicate the relevance of sicence and technology for society.
The second has to do with the way we mentor and assist scientists and engineers that seek to become entrepreneurs. What is the role of universities, government and private sector to achieve this task.
Third area is corporate entrepreneurship, industrial venturing and the attitude EU large corporations have towards change.
Finally demands side innovation policy: public procurement and the setting of challenges and ambitious goals, where sometimes the role of the government should not be to provide the means to achieve these goals, but to promise to act as first buyer for the best solutions for a specific challenge.
The document discusses various funding opportunities for rare disease research at the European and national levels. At the European level, it describes the E-Rare program which coordinates rare disease research funding across multiple European countries through joint transnational calls. It also outlines relevant funding opportunities through the European Commission's Framework Programs, including Horizon 2020, and public-private partnerships like the Innovative Medicines Initiative. At the national level, it analyzes the different approaches countries take to funding rare disease research and the varying budgets invested.
The document discusses the potential benefits of eHealth (ICT for health) in Europe. It notes that while the health sector employs over 9% of the EU workforce, ICT penetration in health is relatively low compared to other sectors. eHealth can improve efficiency and productivity, support chronic disease management and preventive care, and empower patients. The EU is a world leader in deploying ICT in primary care settings. Further development of eHealth requires addressing issues like interoperability, business models, and research into areas like personalized medicine.
Juli Mylona - Bioconomy - plant science and agriculture. Future funding under...epsoeurope
Presentation from Juli Mylona, Directorate FAFB, DG Research and Innovation, European Commission, at the 7th EPSO Conference, 2 Sept 2013.
"Bioconomy - plant science and agriculture. Future funding under Horizon 2020"
This document provides an overview of Horizon 2020, the EU's research and innovation program for 2014-2020. Key points include:
- Horizon 2020 has a budget of over €70 billion and aims to drive economic growth and jobs through support for research and innovation.
- It focuses on three main priorities: excellent science, industrial leadership, and addressing societal challenges.
- The program simplifies participation rules and funding to increase access and participation for all member states and organizations.
- Horizon 2020 also aims to strengthen the European Research Area and boost the involvement of small and medium enterprises.
Johanna Adami is the director and head of health at VINNOVA, Sweden's innovation agency. She discusses Sweden's national innovation strategy and VINNOVA's role in funding research and innovation. VINNOVA aims to address grand challenges like health, the environment, and an aging population through collaborative projects bringing together researchers, industries, and other stakeholders both within Sweden and internationally. VINNOVA's health programs support personalized medicine, life sciences, and reforming healthcare to be more innovation-focused. The future roadmap involves stronger public-private partnerships and providing evidence of innovation outcomes.
ICT and Horizon 2020, Iddo Bante 2013-08-22Iddo Bante
This document provides an overview of the Horizon 2020 framework program for research and innovation from 2014-2020. Key points include:
- Horizon 2020 has a budget of €70.2 billion, focusing on excellent science, industrial leadership, and societal challenges.
- ICT is addressed under the industrial leadership priority, with an estimated budget of €8-9 billion. This focuses on areas like future internet, cloud computing, robotics, microelectronics, and photonics.
- Public-private partnerships (PPPs) will play an important role in implementing ICT and other industry-related activities. Both existing and new PPPs are outlined.
- The goals are to strengthen European leadership in key technologies,
Hungary is the right place for investment and cooperation in the fields of he...Tristan Azbej, PhD
Hungary is located in central Europe and is a member of the EU. It has a population of around 10 million and its economy has grown in recent years. Hungary has a competitive tax system for businesses and is focusing on reindustrialization through sectors like automotive, machinery, healthcare, food, green technology, and defense. It aims to participate in developing new diagnostic methods using bioelectronic technologies. Hungary has a large pharmaceutical industry and over 50% of its biotech companies work in red biotech. It is focusing on clinical trials, biomarkers, customized care, and analyzing big data in healthcare. Hungary also has a large medical tourism industry focused on thermal baths and mineral springs.
European innovation scoreboard 2022-KI0922386ENN (1).pdfPaperjam_redaction
The European Innovation Scoreboard 2022 report provides the following key findings:
1. Almost all EU Member States have increased their innovation performance since 2015, but the lowest performing countries are falling further behind.
2. Between 2021 and 2022, innovation performance declined for eight Member States and improved for 19.
3. Based on their innovation performance relative to the EU average, Member States fall into four groups: Innovation Leaders, Strong Innovators, Moderate Innovators, and Emerging Innovators.
4. At the global level, the EU has overtaken Japan in innovation performance and closed part of the gap with some other competitors like South Korea and the US.
The document discusses EU and national funding opportunities for public health research. It outlines that UK organizations can continue applying to Horizon 2020 funding while the UK remains in the EU. The EU Public Health Programme aims to improve health policies and protect citizens from health threats. It provides grants and joint actions for members states on topics like chronic diseases, tobacco control, and antimicrobial resistance. Horizon 2020 also has funding calls in health and demographic change on areas like rare diseases, regenerative medicine, and economic evaluation in health. National funding in Ireland is also outlined from the Health Research Board.
La Sociedad Española de Cardiología (SEC) es una organización científica sin ánimo de lucro con la misión de reducir el impacto adverso de las enfermedades cardiovasculares y promover una mejor salud cardiovascular en la ciudadanía.
Ponencia presentada por la Dra. Marisol Bravo Amaro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
More Related Content
Similar to Research and Innovation in Cardiovascular Diseases: The EU perspectives
The New EU Framework Programme for Research and Innovationmathgear
Horizon 2020 is the new EU framework programme for research and innovation from 2014 to 2020 with a budget of nearly €80 billion. It aims to stimulate economic growth and jobs by supporting research and innovation. The three priorities are excellent science, industrial leadership, and addressing societal challenges. It provides simplified single set of rules and funding rates to make participating easier for organizations. The first calls saw over 36,000 proposals requesting €80 billion in funds, with around 14% success rate.
Presentation at the 3rd European Sustainable Phosphorus Conference (ESPC3), Helsinki, 11 - 13 June 2018, co-organised by the Baltic Sea Action Group (BSAG) and the European Sustainable Phosphorus Platform (ESPP), brought together nearly 300 participants from 30 countries talking about nutrient recycling and stewardship.
See for all information and outcomes www.phosphorusplatform.eu/ESPC3
Euro-Med cooperation in the Horizon
* Regional focus – while acknowledging diversity within the region
* Focus on common challenges – what are the problems that R&I can help addressing, and how?
* Instruments – to support collaborative research, to support R&I policy dialogue, to coordinate initatives by EU, its Member States and MPCs, to integrate programmes/Art 185, to foster innovation !
* Building on ongoing projects –e.g. MEDSPRING, ERANET MED
EuroBioForum 2013 - Day 1 | Wolfgang EberleEuroBioForum
EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany
http://www.eurobioforum.eu/2013
=======================================
# NATIONAL PERSPECTIVES #
Belgium
Working across disciplines for our health benefit - From successful strategies for biotech and nanotech to Nanotech for Health in Flanders
Wolfgang Eberle
Funded Program Manager Life Science Technologies Imec
=======================================
http://www.eurobioforum.eu
The document provides an overview of Horizon 2020, the European Union's research and innovation programme for 2014-2020. Key points include:
- It has a budget of over €70 billion, a 25% increase from the previous 2007-2013 period.
- It aims to boost jobs and growth by supporting research, innovation and addressing societal challenges.
- It simplifies funding with single rules, faster grants, and less auditing.
- Funding is organized around three priorities: excellent science, industrial leadership, and societal challenges like health, energy, transport and climate.
- It emphasizes challenge-based and cross-disciplinary research with participation from SMEs.
- Horizon 2020 aims to strengthen the
The SME Innovation Instrument, Horizon2020 and Talent Europe. A discussion by...Alberto Minin
I provide a quick introduction to the Meridian Fellowship on Social Innovation and to my project, Talent Europe,
I will then present some of the latest numbers regarding the implementation of the SME Innovation instrument, one of the most innovative parts of the 8th presentation Framework program called Horizon 2020
I will briefly share with you three concepts that I think might be interesting to explore as a basis of a useful comparison between Europe and US science and technology Policy.
What I am seeking to do as a Meridian Fellow is to expand my expertise on science and technology policy and to contribute to the debate around this topic that is developing in Europe. I think that there are better ways to engage and to empower EU talent, and to make it become key player of EU Economic Recovery and competitiveness
The US had been a continuous source of inspiration for the EU debate on science and technology, and more in general on innovation policy.
Later on I will discuss about the SME innovation instrument that had been inspired in part by the SBIR program here in the US.
Not only policy makers and scholars have been guiding this exchange of ideas and experiences, but also US Embassies in Europe have been very important in sharing with Europe some news. I am very familiar with the case of the US Embassies in Italy. The past three Ambassadors have been evangelists of messages and priorities. Ronald Spogli emphasized the role of high tech entrepreneurs in society, David Thorne has focused on the role the digital economy can have a driver of growth, more recently the sitting ambassador, John Phillips is very vocal about the benefits that Italy could derive by a more efficient judiciary system
My experience as scholar, and teacher is telling me that the debate on innovation in Europe is desperately in need of some fresh air and new ideas.
I believe that there are four areas where we can look.
The first one has to do with new original ways to communicate the relevance of sicence and technology for society.
The second has to do with the way we mentor and assist scientists and engineers that seek to become entrepreneurs. What is the role of universities, government and private sector to achieve this task.
Third area is corporate entrepreneurship, industrial venturing and the attitude EU large corporations have towards change.
Finally demands side innovation policy: public procurement and the setting of challenges and ambitious goals, where sometimes the role of the government should not be to provide the means to achieve these goals, but to promise to act as first buyer for the best solutions for a specific challenge.
The document discusses various funding opportunities for rare disease research at the European and national levels. At the European level, it describes the E-Rare program which coordinates rare disease research funding across multiple European countries through joint transnational calls. It also outlines relevant funding opportunities through the European Commission's Framework Programs, including Horizon 2020, and public-private partnerships like the Innovative Medicines Initiative. At the national level, it analyzes the different approaches countries take to funding rare disease research and the varying budgets invested.
The document discusses the potential benefits of eHealth (ICT for health) in Europe. It notes that while the health sector employs over 9% of the EU workforce, ICT penetration in health is relatively low compared to other sectors. eHealth can improve efficiency and productivity, support chronic disease management and preventive care, and empower patients. The EU is a world leader in deploying ICT in primary care settings. Further development of eHealth requires addressing issues like interoperability, business models, and research into areas like personalized medicine.
Juli Mylona - Bioconomy - plant science and agriculture. Future funding under...epsoeurope
Presentation from Juli Mylona, Directorate FAFB, DG Research and Innovation, European Commission, at the 7th EPSO Conference, 2 Sept 2013.
"Bioconomy - plant science and agriculture. Future funding under Horizon 2020"
This document provides an overview of Horizon 2020, the EU's research and innovation program for 2014-2020. Key points include:
- Horizon 2020 has a budget of over €70 billion and aims to drive economic growth and jobs through support for research and innovation.
- It focuses on three main priorities: excellent science, industrial leadership, and addressing societal challenges.
- The program simplifies participation rules and funding to increase access and participation for all member states and organizations.
- Horizon 2020 also aims to strengthen the European Research Area and boost the involvement of small and medium enterprises.
Johanna Adami is the director and head of health at VINNOVA, Sweden's innovation agency. She discusses Sweden's national innovation strategy and VINNOVA's role in funding research and innovation. VINNOVA aims to address grand challenges like health, the environment, and an aging population through collaborative projects bringing together researchers, industries, and other stakeholders both within Sweden and internationally. VINNOVA's health programs support personalized medicine, life sciences, and reforming healthcare to be more innovation-focused. The future roadmap involves stronger public-private partnerships and providing evidence of innovation outcomes.
ICT and Horizon 2020, Iddo Bante 2013-08-22Iddo Bante
This document provides an overview of the Horizon 2020 framework program for research and innovation from 2014-2020. Key points include:
- Horizon 2020 has a budget of €70.2 billion, focusing on excellent science, industrial leadership, and societal challenges.
- ICT is addressed under the industrial leadership priority, with an estimated budget of €8-9 billion. This focuses on areas like future internet, cloud computing, robotics, microelectronics, and photonics.
- Public-private partnerships (PPPs) will play an important role in implementing ICT and other industry-related activities. Both existing and new PPPs are outlined.
- The goals are to strengthen European leadership in key technologies,
Hungary is the right place for investment and cooperation in the fields of he...Tristan Azbej, PhD
Hungary is located in central Europe and is a member of the EU. It has a population of around 10 million and its economy has grown in recent years. Hungary has a competitive tax system for businesses and is focusing on reindustrialization through sectors like automotive, machinery, healthcare, food, green technology, and defense. It aims to participate in developing new diagnostic methods using bioelectronic technologies. Hungary has a large pharmaceutical industry and over 50% of its biotech companies work in red biotech. It is focusing on clinical trials, biomarkers, customized care, and analyzing big data in healthcare. Hungary also has a large medical tourism industry focused on thermal baths and mineral springs.
European innovation scoreboard 2022-KI0922386ENN (1).pdfPaperjam_redaction
The European Innovation Scoreboard 2022 report provides the following key findings:
1. Almost all EU Member States have increased their innovation performance since 2015, but the lowest performing countries are falling further behind.
2. Between 2021 and 2022, innovation performance declined for eight Member States and improved for 19.
3. Based on their innovation performance relative to the EU average, Member States fall into four groups: Innovation Leaders, Strong Innovators, Moderate Innovators, and Emerging Innovators.
4. At the global level, the EU has overtaken Japan in innovation performance and closed part of the gap with some other competitors like South Korea and the US.
The document discusses EU and national funding opportunities for public health research. It outlines that UK organizations can continue applying to Horizon 2020 funding while the UK remains in the EU. The EU Public Health Programme aims to improve health policies and protect citizens from health threats. It provides grants and joint actions for members states on topics like chronic diseases, tobacco control, and antimicrobial resistance. Horizon 2020 also has funding calls in health and demographic change on areas like rare diseases, regenerative medicine, and economic evaluation in health. National funding in Ireland is also outlined from the Health Research Board.
Similar to Research and Innovation in Cardiovascular Diseases: The EU perspectives (20)
La Sociedad Española de Cardiología (SEC) es una organización científica sin ánimo de lucro con la misión de reducir el impacto adverso de las enfermedades cardiovasculares y promover una mejor salud cardiovascular en la ciudadanía.
Ponencia presentada por la Dra. Marisol Bravo Amaro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
Ponencia presentada por el Dr. Armando Oterino Manzanas en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
Ponencia presentada por la Dra. Miriam Martín Toro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
Ponencia presentada por los Dres. M.ª Dolores Mesa Rubio, Javier Mora Robles, Margarita Reina Sánchez, M.ª José Castillo Moraga y José Luis Bianchi Llave en el CardioTV Focus, publicado el 25 de abril de 2024 en la Casa del Corazón (Madrid).
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Discover the benefits of homeopathic medicine for irregular periods with our guide on 5 common remedies. Learn how these natural treatments can help regulate menstrual cycles and improve overall menstrual health.
Visit Us: https://drdeepikashomeopathy.com/service/irregular-periods-treatment/
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7shruti jagirdar
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdfOsvaldo Bernardo Muchanga
GASTROINTESTINAL INFECTIONS AND GASTRITIS
Osvaldo Bernardo Muchanga
Gastrointestinal Infections
GASTROINTESTINAL INFECTIONS result from the ingestion of pathogens that cause infections at the level of this tract, generally being transmitted by food, water and hands contaminated by microorganisms such as E. coli, Salmonella, Shigella, Vibrio cholerae, Campylobacter, Staphylococcus, Rotavirus among others that are generally contained in feces, thus configuring a FECAL-ORAL type of transmission.
Among the factors that lead to the occurrence of gastrointestinal infections are the hygienic and sanitary deficiencies that characterize our markets and other places where raw or cooked food is sold, poor environmental sanitation in communities, deficiencies in water treatment (or in the process of its plumbing), risky hygienic-sanitary habits (not washing hands after major and/or minor needs), among others.
These are generally consequences (signs and symptoms) resulting from gastrointestinal infections: diarrhea, vomiting, fever and malaise, among others.
The treatment consists of replacing lost liquids and electrolytes (drinking drinking water and other recommended liquids, including consumption of juicy fruits such as papayas, apples, pears, among others that contain water in their composition).
To prevent this, it is necessary to promote health education, improve the hygienic-sanitary conditions of markets and communities in general as a way of promoting, preserving and prolonging PUBLIC HEALTH.
Gastritis and Gastric Health
Gastric Health is one of the most relevant concerns in human health, with gastrointestinal infections being among the main illnesses that affect humans.
Among gastric problems, we have GASTRITIS AND GASTRIC ULCERS as the main public health problems. Gastritis and gastric ulcers normally result from inflammation and corrosion of the walls of the stomach (gastric mucosa) and are generally associated (caused) by the bacterium Helicobacter pylor, which, according to the literature, this bacterium settles on these walls (of the stomach) and starts to release urease that ends up altering the normal pH of the stomach (acid), which leads to inflammation and corrosion of the mucous membranes and consequent gastritis or ulcers, respectively.
In addition to bacterial infections, gastritis and gastric ulcers are associated with several factors, with emphasis on prolonged fasting, chemical substances including drugs, alcohol, foods with strong seasonings including chilli, which ends up causing inflammation of the stomach walls and/or corrosion. of the same, resulting in the appearance of wounds and consequent gastritis or ulcers, respectively.
Among patients with gastritis and/or ulcers, one of the dilemmas is associated with the foods to consume in order to minimize the sensation of pain and discomfort.
Osvaldo Bernardo Muchanga-GASTROINTESTINAL INFECTIONS AND GASTRITIS-2024.pdf
Research and Innovation in Cardiovascular Diseases: The EU perspectives
1. Research and
Innovation
Dr Karim Berkouk
Deputy Head of Unit for Medical Research and Ageing
Health Directorate
Research & Innovation DG
European Commission
Madrid, 25 June2014
Research and Innovation in
Cardiovascular Diseases -
The EU perspectives
3. Research and
Innovation
• Ageing population
• Increased disease burden:
chronic diseases
• Health & care sector
unsustainable: under pressure to
reform
• Health industry under pressure
for innovative solution
Health main challenges
4. Research and
Innovation
• First cause of death in Europe
• Costs : 200 Billion per year
• Elderly population
• Co-morbidities (diabetes and obesity)
• Limited innovation in recent years
• Stratification of patients to predict
successful treatment
CVD main
challenges
6. Research and
Innovation
FP 7 - Health - State of Play
Key figures
5,5 B€ invested
1054 projects
12 505 participations
3 615 organisations
123 countries
First outcomes
(on 349 closed projects)
11 879 publications
3,2 average SJR* publication
227 patent applications
31 spin-offs created
* SCImago Journal Ranking
7. Research and
Innovation
FP 7 - CVD - State of Play
Key figures
810 M€ invested
371 projects
1,788 participations
907 organisations
61 countries
First outcomes
(on 22 closed Health projects)
1,165 publications
2,5 (7,1) average SJR*
publication
27 patent applications
* SCImago Journal Ranking
8. Research and
Innovation
Collabora-
tive
projects -
€620M
77%
Frontier –
€113M
14%
Training –
€74M
9%
EU CVD research –
what’s being funded
• translational research
atherosclerosis
arrhythmias
heart failure
cardiomyopathies
hypertension
congenital disease
stroke
biomarkers, drug target
discovery and validation
tissue regeneration
imaging
• comparative
effectiveness research
• investigator-driven trials
• public health
Number of projects: 71
Total Costs : € 1,041 million
EU Contribution : € 907million*
*data cover 2007-2013
9. Research and
Innovation
FP 7 – CVD MS Regions
funding
In million € (m€)
0
0 - 0,5
0,5 - 1
1 - 0
0 - 1
1 - 3
3 - 30
30 - 32
32 - 37
37 +
B
N
10. Research and
Innovation
FP 7 – CVD Spanish
Regions funding
ES11
ES12
ES13
ES21
ES22
ES23
ES24
ES30
ES41
ES42ES43
ES51
ES52
ES61
ES62 SPAIN key figures
EC Contribution : 49.878.105
Total Costs : 65.817.228
Number of projects : 79
Number of participations : 141
Number of organisations : 81
Average amount by participations : 353.745
11. Research and
Innovation
Average EC contribution in
CVD projects
682.991
636.870
603.910
532.153
503.037
499.993
484.876
483.157
477.375
425.592
417.189
399.831
369.400
368.340
353.745
349.414
339.891
332.963
265.484
257.132
236.327
234.854
227.135
217.468
215.038
213.240
191.590
190.921
190.907
189.136
167.998
152.486
104.899
100.383
0
0
0
382.185
Netherl…
Finland
Sweden
Israel
Germany
Switzer…
Belgium
France
United…
Turkey
Iceland
Denmark
Greece
Ireland
Spain
Italy
Austria
Norway
Serbia
Portugal
Luxemb…
Bulgaria
Lithuania
Hungary
Czech…
Moldov…
Latvia
Poland
Romania
Slovakia
Cyprus
Estonia
Slovenia
Croatia
Malta
14. Research and
Innovation
The Multiannual Financial Framework
2014-2020: European Council conclusions, 8 February 2013
• Key challenge: stabilise the financial and economic
system while taking measures to create economic
opportunities
1. Smart & inclusive growth (€451 billion)
2. Sustainable growth, natural resources (€373 billion)
3. Security and citizenship (€16 billion)
4. Global Europe (€58 billion)
5. Administration (€61.6 billion)
Education,
Youth, Sport
Connecting
Europe
Cohesion
Competitive
Business
SMEs
HORIZON
2020
TOTAL
€960 billion
15. Research and
Innovation
What Horizon is 2020 about
− Responding to the economic crisis to invest in
future jobs and growth
− Addressing people’s concerns about their
livelihoods, safety and environment
− Strengthening the EU’s global position in
research, innovation and technology
http://ec.europa.eu/research/horizon2020
The EU’s 2014-20 programme
for research & innovation
A core part of Europe 2020,
Innovation Union &
European Research Area
16. Research and
Innovation
Three
priorities
•Excellent
science
•Industrial
leadership
•Societal
challenges
• European Research Council
• Future and Emerging Technologies
• Marie Skłodowska-Curie actions
• Research infrastructures
• Leadership in
enabling and
industrial
technologies
• Access to risk
finance
• Innovation in
SMEs
• Health, demographic
change and wellbeing
• Food security,
sustainable
agriculture and
forestry, marine and
maritime and inland
water research and
the Bioeconomy
• Secure, clean and
efficient energy
• Smart, green and
integrated transport
• Climate action,
environment,
resource efficiency
and raw materials
• Inclusive, innovative
and reflective
societies
• Secure societies
• Science with and for
society
• Spreading excellence
and widening
participation
17. Research and
Innovation
Innovation Investment Package
€22 billion Innovation Investment Package
Joint Technology Initiatives (under Article 187)
• Innovative Medicines Initiative 2
• Clean Sky (Aeronautics) 2
• Fuel Cell and Hydrogen 2
• Bio-based Industries
• Electronic components and systems
Joint programmes (under Article 185)
• European and Developing Countries Clinical Trials
Partnership (EDCTP) 2
• European Metrology Research Programme 2
• Eurostars (for SMEs) 2
• Active and Assisted Living 2
18. Research and
Innovation
General opening
• Horizon 2020 is open to participation from across the
world
• Automatic funding:
• Member States (including overseas departments and
overseas territories)
• Associated Countries
• exhaustive list of countries in annex to work
programme (but: no longer BRIC + Mexico in this list!)
• Participants from other countries only funded in
exceptional cases:
• when provision is made in the call text
• bilateral agreement (e.g. Health challenge – NIH)
• when the Commission deems it essential (case by case
assessment)
20. Research and
Innovation
Less prescriptive topic texts
Two-year work programme
Stronger focus on end users
Broad topics
Challenge-driven
Health, Demographic change and
wellbeing - aim
Funding: € 7.5 Billion
21. Research and
Innovation
Advancing active and healthy ageing
Integrated, sustainable, citizen-centred care
Improving health information, data exploitation and
providing an evidence base for health policies and regulation
Innovative treatments and technologies
Improving diagnosis
7 Focus Areas
Effective health promotion, disease prevention,
preparedness and screening
Understanding health, ageing & disease
22. Research and
Innovation
• European Innovation Partnership on Active and Healthy
Ageing
• Global Alliance for Chronic Diseases (GACD) – Diabetes
(2014)
• Joint Programming Initiatives on neurodegenerative
diseases (JPND); 'More Years, Better Life's; & Global
Research Collaboration for Infectious Disease
Preparedness (2014)
• ERANETS : Cancer, Systems medicine & rare diseases
(2014); Brain-related disorders, antimicrobial
resistance, cardiovascular diseases (2015)
Support for European and
International Initiatives
23. Research and
Innovation
Strategic Initiatives
Innovative Medicines Initiative 2
www.imi.europa.eu
European & Developing Countries
Clinical Trials Partnership (EDCTP2)
www.edctp.org
Active and Assisted Living 2
www.aal-europe.eu
European Innovation Partnership
on Active and Healthy Ageing
https://webgate.ec.europa.eu/eipaha
24. Research and
Innovation
Clinical Trials – Horizon 2020
• Key element of health research supported in
Horizon 2020: no innovation without clinical
trials!
• Specific Programme (legal basis): "translation of
research findings into the clinic, in particular through the conduct
of clinical trials […] is essential"
• 2014/15 calls: Over €300 million of funding
earmarked for clinical trials
• Emphasis on SMEs and on investigator-driven
clinical trials
25. Research and
Innovation
New EU Clinical Trials
Regulation
• Responds to criticism of current EU Clinical
Trials Directive:
• Single submission portal for multinational trials
• Joint assessment by member states' competent authorities
• Tacit-approval deadlines
• Reduced administrative burden (low-risk trials)
• Applicable two years after publication (+
transition period)
26. Research and
Innovation
Innovation Union Commitment n°7
Ensure stronger involvement of SME in
future EU R&I programmes
*
European Council 4 February 2011
Commission is invited to explore the
feasibility of a Small Business Innovation
Research Scheme
Innovation Initiatives
28. Research and
Innovation
More opportunities
for SMEs
• Integrated approach - around 20% of the
total budget for societal challenges and
LEITs to go to SMEs
• A new SME instrument will be used across
all societal challenges as well as for the
LEITs
• A dedicated activity for research-intensive
SMEs in 'Innovation in SMEs'
• 'Access to risk finance' will have a strong
SME focus (debt and equity facility)
• COSME and H2020 are complementary
programmes to generate growth and jobs
Image courtesy of Vlado/ FreeDigitalPhotos.net
29. Research and
Innovation
SME instrument
Concept &
Feasibility
Assessment
Innovation
R&D activities
Commercialisation
Phase 2Phase 1 Phase 3
Idea Market
• Feasibility of concept
• Risk assessment
• IP regime
• Partner search
• Design study
• Development,
prototype, testing
• Miniaturisation/design
• Clinical trials
• Etc.
• Facilitate access to
private finance
• Support via networking,
training, coaching,
knowledge sharing,
dissemination
Lump sum:
~ 50.000 €
~ 6 months
Output-based payments:
1 to 5 M€
12 to 36 months
No direct funding
Deadlines: 2/3 cut off dates in 2014 for phase 1 & 2